Dermatological Center Bonn Friedensplatz, Bonn, Germany.
Future Oncol. 2017 Nov;13(27):2413-2428. doi: 10.2217/fon-2017-0247. Epub 2017 Aug 14.
BF-200 ALA is a combination of a nanoscale-lipid vesicle formulation and the prodrug 5-aminolevulinic acid (5-ALA). The nanoemulsion stabilizes the prodrug and enhances its penetration through the stratum corneum. It has shown excellent therapeutic results in both lesion and field-directed photodynamic therapy of actinic keratosis (AK). AK is an early form of epidermal neoplasia and a precursor of invasive cutaneous squamous cell carcinoma. It is characterized by the combination of visible neoplastic lesions and surrounding tissue also harboring tumorigenic UV-induced mutations: a concept called field cancerization. A selective, field-directed treatment is ideal to meet the requirements of field change. Here, we review the clinical data on BF-200 ALA for AK along with a summary of molecular mechanisms and future perspectives.
BF-200 ALA 是一种纳米脂质囊泡制剂和前体药物 5-氨基酮戊酸（5-ALA）的组合。纳米乳剂稳定前体药物并增强其穿过角质层的渗透。它在光动力疗法治疗光化性角化病（AK）的病变和区域导向治疗中均显示出极佳的治疗效果。AK 是表皮肿瘤的早期形式，也是侵袭性皮肤鳞状细胞癌的前体。其特征是可见的肿瘤病变与周围组织的结合，也存在致瘤性的紫外线诱导突变：这一概念称为“癌化灶”。选择性的、区域导向的治疗是满足区域变化要求的理想方法。在这里，我们回顾了 BF-200 ALA 治疗 AK 的临床数据，并总结了分子机制和未来展望。
